Soligenix Inc. (NASDAQ:SNGX) shares surged on Thursday as the company announced positive results from its Phase 2a ...

A new oral drug is showing promise for treating oral and genital ulcers in people with Behçet's syndrome, according to research presented this week at the American College of Rheumatology (ACR) ...

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and ...

Soligenix Inc.’s phase IIa study of SGX-945 (dusquetide) for treating oral ulcers in those with Behçet's disease showed biological efficacy in the proof-of-concept study. The positive results ...

From oral cancer to vitamin deficiencies, mouth ulcers and cracks can indicate a lot of hidden diseases. Know from the study here.

Under this IND, the pilot clinical trial of SGX945 will be an open-label study that will enroll approximately 25 patients age 18 years or older with mild to moderate Behçet's disease active oral ...

news No Evidence for Benefits of Opioids After Pediatric Tonsillectomy ... August 12, 2019 Otezla Approved to Treat Oral Ulcers Associated With Behçet’s Disease ... By Diana Ernst, RPh July 22 ...

Major signs and symptoms usually include mouth sores (approximately 95% of patients), skin rashes and lesions (approximately 50% of patients), genital sores (approximately 50% of patients), leg ...

(RTTNews) - Soligenix, Inc. (SNGX) Thursday said it received clearance from the Food and Drug Administration (FDA) for Phase 2a study of SGX945 to treat aphthous ulcers in Behcet's disease ...

Investigational New Drug (IND) application for a Phase 2a clinical trial for SGX945 (dusquetide) for aphthous ulcers in Behçet's disease. Behçet disease is a rare vasculitic disorder that can ...